New hypertension drug combo enters first human tests
NCT ID NCT07312799
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial will test two experimental drugs, AD-2321 and AD-2322, in 41 healthy adults to see how they interact in the body. The study focuses on safety and how the drugs are processed, not on treating high blood pressure. Results will guide future studies in patients with hypertension.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- AD-2321 and AD-2322 oral tablets
- What this could lead to
- If successful, this study could help determine safe dosing for a future hypertension treatment.
- What could go wrong
- This is a very early Phase 1 trial in healthy volunteers, not patients. It only measures drug levels and safety, not whether the drugs actually lower blood pressure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERTENSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
H+ Yangji Hospital
Seoul, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a few short nights of sleep tip the scales toward high blood pressure?
- Chatbot could put blood pressure control in Patients' hands
- Can a 5-Step chat help tame high blood pressure?
- Can artery scans reveal hidden damage from high blood pressure?
- CRISPR injection could rewrite the future of blood pressure control
- Text messages and nurses: a new strategy to tackle hypertension in tanzania?